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The optimal therapy for steroid-refractory (SR) acute graft-versus-host disease (aGVHD) is undeﬁned. We
studied patients with SR aGVHD, comparing extracorporeal photopheresis (ECP; n ¼ 57) and anticytokine
therapy (n ¼ 41). In multivariate analyses, ECP, adjusted for steroid dose (odds ratio, 3.42; P ¼ .007), and grade
>II aGVHD (odds ratio, 68; P < .001) were independent predictors of response. ECP therapy, adjusted for
conditioning regimen intensity and steroid dose, was associated with superior survival (hazard ratio [HR], 4.6;
P ¼ .016) in patients with SR grade II aGVHD. Grade >II aGVHD at onset of salvage therapy (HR, 9.4; P < .001)
and lack of response to therapy (HR, 3.09; P ¼ .011) were associated with inferior survival. These ﬁndings
require validation in a prospective randomized study.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION for SR aGVHD [10-12]. The outcomes of ECP and anticytokine
Graft-versus-host disease (GVHD) remains an important
complication of allogeneic stem cell transplantation (allo-
SCT). Despite prophylaxis, International Bone Marrow Trans-
plantation Registry severity index grade B-D acute GVHD
(aGVHD) occurs in 39%-59% of patients undergoing T
cellereplete related or unrelated donor allo-SCT [1]. Cortico-
steroids are the cornerstone of initial therapy for grade II or
grade B-D aGVHD [2-4], leading to complete response (CR) in
25%-69% of patients [5,6]. Patients not responding to steroids
have a dismal prognosis, with poor survival [2,7].
Numerous agents for treating steroid-refractory (SR)
aGVHD have been studied [7,8]. The French group published
its experience in a cohort of 93 patients with SR aGVHD using
either inolimumab or etanercept [9]. Single-center studies
have suggested extracorporeal photopheresis (ECP) using
UV-A irradiation of peripheral blood mononuclear cells after
incubation with 8-methoxypsoralen as effective treatmenttherapy have not been compared previously. In the present
study, we performed a retrospective comparison of the efﬁ-
cacy of second-line therapy in 98 patients treatedwith either
ECP (n ¼ 57) or anticytokine therapy (n ¼ 41).
METHODS
Consecutive patients undergoing allo-SCT after January 2005 and devel-
oping grade II (according to modiﬁed Glucksberg criteria [13]) SR aGVHD
(deﬁned as progression after 3 days or no response after 7 days of initial
therapy) and treatedwith ECP (Nashville, Tennessee, USA, n¼ 13;Nottingham,
UK, n¼ 19; Vienna, Austria, n¼ 25) orwith anticytokine therapy (Paris, France,
n¼ 41)were included. Other inclusion criteriawere corticosteroids at a dose of
least1mg/kg/day alone as ﬁrst-line therapy for aGVHDwith continuation of
calcineurin inhibitors. Anticytokine therapy consisted of inolimumab or eta-
nercept (after 2003). Given that the ECP cohort was recruited after 2005, only
a subsetofpatients fromtheFrenchdataset (41patientswithSRaGVHDtreated
with inolimumaboretanercept after 2005)was included in the non-ECP group
[9]. ECPwas initiated at a frequency of 2-3 treatments per week on aweekly or
biweekly basis. ECP therapywas stopped aftermaximal responsewas achieved
(Austria and UK) or was tapered gradually (Tennessee, USA).
Response was deﬁned as CR (disappearance of signs of GVHD from all
organs involved), partial response (PR; any improvement in GVHD), or
progressive disease (no response or worsening of GVHD in at least 1 organ).
The use of additional immunosuppressive agents after ECP or anticytokine
therapy for controlling aGVHD was considered progressive disease.
Response was assessed at 4 weeks after anticytokine therapy or at the end of
ECP (a median of 45 days after the start of ECP). Given the variability of
response assessment and retrospective nature of the analyses, the primary
focus of this analysis was overall survival (OS).
Descriptive statistics were calculated and groups were compared using
the chi-squared test (nominal) and Wilcoxon rank-sum test (continuous)
respectively. Two-proportion tests were used to compare stage of GVHD
before and after therapy. OS was measured from the initiation of ECP or
anticytokine therapy using Kaplan-Meier survival curves and compared
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ipient sex
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M. Jagasia et al. / Biol Blood Marrow Transplant 19 (2013) 1124e1135 1131using the log-rank test [14]. Multivariate analyses were performed using
logistic regression or Cox proportional hazards regression. All statistical
analyses were conducted using SPSS version 19 (IBM, Armonk, NY) or R
version 2.1.1 (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Table 1 provides the details on clinical and aGVHD char-
acteristics and transplantation outcomes. The anticytokine
therapy group had a higher proportion of patients receiving T
cellereplete allo-SCT (90% versus 77%; P ¼ .028), stage 3-4
skin aGVHD (49% versus 25%; P ¼ .013), grade III-IV aGVHD
(63% versus 28%; P ¼ .001), and use of steroids at a dose 2
mg/kg (100% versus 79%; P¼ .02). The ECP group had a higher
proportion of patientswith stage 3-4 liver aGVHD (25%versus
2%; P ¼ .003), and a higher proportion of patients with
involvement of at least 3 organs (23% versus 5%; P¼ .015). All
10 patientswith donor lymphocyte infusioneinduced aGVHD
were in the ECP group. ECP or anticytokine therapy was
initiated at amedian of 45 days (range, 8 to 99 days) after allo-
SCT or donor lymphocyte infusion and after a median of 19
days (range, 2 to 82 days) of systemic corticosteroids for
initial therapy for aGVHD. The median number of ECP treat-
ments was 12 (range, 2 to 45) over a median duration of 45
days (range, 14 to 293 days).
Both overall response (CRþPR) and CR were signiﬁcantly
higher in the ECP group compared with the anticytokine
group (66% versus 32%, P ¼ .001; 54% versus 20%, P ¼ .001).
Figure 1 outlines patient responses to ECP and anticytokine
therapy stratiﬁed by stage 3-4 organ involvement, grade III-
IV aGVHD, and number of organs involved. Univariate anal-
yses associated with response and survival are detailed in
Table 1 for both groups, and Figure 2 presents a survival plot.
In multivariate analyses, ECP, adjusted for steroid dose
(1 mg/kg versus >1 mg/kg), was an independent predictor of
response (odds ratio [OR], 3.42; 95% conﬁdence interval [CI],
1.39-8.37; P ¼ .007), as was grade of aGVHD (II versus >II),
adjusted for ECP or anticytokine therapy and conditioning
regimen intensity (OR, 68; 95% CI, 16-290; P < .001).
The median duration of follow-up of surviving patients
after therapy was 30.2 months (range, 2.1 to 78 months; 37.9
months for the ECP group versus 17 months for the anti-
cytokine group; P < .001), and the 2-year OS for all patients
was 45.2%. In multivariate analysis, ECP therapy, adjusted for
conditioning regimen intensity and steroid dose, was an
independent predictor of superior survival (hazard ratio
[HR], 2.12; 95% CI, 1.13-3.96; P ¼ .018). Furthermore, ECP
therapy, adjusted for conditioning regimen intensity and
steroid dose, was associated with superior survival (HR, 4.6;
95% CI, 1.33-16.3; P ¼ .016) in patients with SR grade II
aGVHD. Grade>II aGVHD at the onset of salvage therapy (HR,
9.4; 95% CI, 4.73-18.8; P < .001) and lack of response to
therapy (HR, 3.09; 95% CI, 1.2-7.4; P ¼ .011), adjusted for
conditioning regimen intensity and type of GVHD therapy,
were associated with inferior survival.
In multivariate analyses, ECP therapy, adjusted for steroid
dose, was associated with signiﬁcantly lower nonrelapse
mortality (NRM) (HR, 0.45; 95% CI, 0.23-0.87; P¼ .018). Grade
>II aGVHD at onset of salvage therapy, adjusted for condi-
tioning regimen intensity, type of GVHD therapy, and
response to GVHD therapy (HR, 7.4; 95% CI, 2.6-21.2; P< .001),
was associated with a higher NRM.DISCUSSION
Acute GVHD is a complex interplay of donor T cells and
host antigen-presenting cells and B cells. ECP has an
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Figure 1. aGVHD before and after therapy in the ECP and anticytokine groups. Organ-speciﬁc involvement reﬂects stage III-IV aGVHD. P values reﬂect comparison of
aGVHD incidence before and after therapy. Categories without P values were statistically nonsigniﬁcant.
M. Jagasia et al. / Biol Blood Marrow Transplant 19 (2013) 1124e11351132immunomodulatory effect, possiblymediated by T regulatory
cells, leading to decreased proinﬂammatory and increased
anti-inﬂammatory cytokine production [15,16]. Our analysis
suggests a signiﬁcantly higher efﬁcacy of ECP compared with
anticytokine treatment directed at either IL-2R or TNF-
a pathways in patients with SR grade II aGVHD, along with
a signiﬁcant survival advantage for patients receiving ECP.
This study has some limitations. First, the proportions of
patientswith grade III-IV aGVHD and those receiving 2mg/kg
steroids at onset of aGVHD were higher in the anticytokine
therapy group compared with the ECP group. To account for
this potential bias, all multivariate analyses were adjusted for
steroid dose. Although 1 study reported that steroid dose
might not inﬂuence the outcome of aGVHD, comparing 1mg/
kg and 2 mg/kg3, the investigators did not speciﬁcallyFigure 2. Overall survival (OS) stratiﬁed by treatment group. Survival is
measured from onset of ECP or non-ECP intervention.evaluate the outcome of SR patients given the 1 mg/kg dose.
The impact of ECP on survival and NRMwasmost apparent in
SR grade II aGVHD.
Other limitations of the present study are a lack of
homogenous steroid tapering and ECP scheduling, and the
potential differences in response assessment at the various
centers. Although the timing of response assessment was
variable in the 2 patient cohorts, optimal timing of response
assessment for aGVHD therapy remains unclear, with recent
data suggesting day 28 response or a 6-month freedom of
failure from intervention as potential endpoints [17,18].
The optimal timing of intervention, frequency, duration,
and tapering schedule of ECP in SR aGVHD remain important
unanswered questions. ECP probably should be considered
early in the course of SR aGVHD, before signiﬁcant irrevers-
ible end organ damage has been established. The ability of
ECP to spare steroids remains uncertain, but if validated
could decrease steroid-induced complications, both acute
and long-term. In the present study, the median duration of
ECP was 50 days, suggesting that a prolonged course of ECP
might not be necessary. This comprehensive multicenter
analysis suggests that ECP could be an effective second-line
regimen for SR aGVHD, offering a potential survival advan-
tage. Given the limitations of this study, these observations
remain to be validated in a well-designed risk-stratiﬁed
multicenter prospective randomized study.
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Accepted 22 April 2013Inadequate mobilization of peripheral blood progenitor cells (PBPC) is sometimes a limiting factor to proceed
with an autologous hematopoietic cell transplantation (auto-HCT), in an otherwise eligible patient. In such
situations, a bone marrow harvest (BMH) procedure may be considered to achieve the CD34þ target dose for
an autograft. Plerixafor-based mobilization has recently been shown to improve PBPC collection yields.
However, the feasibility and outcomes of BMH in patients failing plerixafor-based mobilization is not known.
We report here, 6 patients who underwent BMH after PBPC mobilization failure with plerixafor. The median
CD34þ yield with plerixafor mobilization and BMH were 1.15 x 10^6/Kg (range, 0.2-1.7  10^6/Kg) and 0.32
(range, 0.12-0.38  10^6/Kg), respectively. Three patients proceeded to an auto-HCT, with only 1 patient
receiving CD34þ cell dose of at least 2  10^6/Kg. While neutrophil recovery was seen, platelet recovery and
red cell transfusion independence were delayed. All 3 autografted patients experienced disease progression
by day +100. These data suggest, limited incremental beneﬁt of a salvage BMH after plerixafor mobilization
failure, cautioning against routine use of this strategy.
 2013 American Society for Blood and Marrow Transplantation.Peripheral blood stem and progenitor cell (PBPC) mobili-
zation failure frequently prevents patientswith hematologicalmalignancies from undergoing a planned autologous hema-
topoietic cell transplantation (auto-HCT) procedure [1]. The
combination of plerixafor and granulocyte colony-stimulating
factor (G-CSF) has been shown to improve PBPC collection
yield and potentially reduce mobilization failure rates in
non-Hodgkin lymphoma and multiple myeloma compared
with mobilization with G-CSF alone [2,3]. Limited data
also suggest safety and feasibility of plerixafor salvage in
patients who appear to be failing chemotherapy-based
mobilization [4,5].
